We are live on
!
Find out more
P
Pfizer Portfolio holdings
AUM
$239M
1-Year Est. Return
232.47%
This Fund
S&P 500
This Quarter
Est. Return
-9.46%
1 Year Est. Return
+232.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.59B
AUM Growth
–
Cap. Flow
+$2.71B
Cap. Flow
% of AUM
104.5%
Top 10 Holdings %
Top 10 Hldgs %
98.36%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haleon
HLN
|
+$1.93B |
| 2 |
BioNTech
BNTX
|
+$417M |
| 3 |
Arvinas
ARVN
|
+$84M |
| 4 |
Allogene Therapeutics
ALLO
|
+$54.3M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$49.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Haleon
HLN
$44.5B
| $1.88B | 72.59% |
+197,228,952
| New | +$1.93B |
|
|
2
BioNTech
BNTX
$23.1B
| $417M | 16.08% |
+3,658,361
| New | +$417M |
|
|
3
Arvinas
ARVN
$517M
| $66.3M | 2.56% |
+3,457,815
| New | +$84M |
|
|
4
Allogene Therapeutics
ALLO
$618M
| $46.9M | 1.81% |
+22,032,040
| New | +$54.3M |
|
|
5
Oric Pharmaceuticals
ORIC
$1.11B
| $43.4M | 1.67% |
+5,376,344
| New | +$49.3M |
|
|
TRML
6
DELISTED
Tourmaline Bio
TRML
| $25.8M | 1% |
+1,272,214
| New | +$32M |
|
7
Wave Life Sciences
WVE
$1.12B
| $23.2M | 0.89% |
+1,875,000
| New | +$25M |
|
8
Biohaven
BHVN
$2.32B
| $18.9M | 0.73% |
+505,645
| New | +$23.6M |
|
|
AKRO
9
DELISTED
Akero Therapeutics
AKRO
| $15.7M | 0.6% |
+562,626
| New | +$17M |
|
10
Pyxis Oncology
PYXS
$150M
| $11M | 0.42% |
+7,032,770
| New | +$20.3M |
|
11
Cardiff Oncology
CRDF
$60.2M
| $10.5M | 0.4% |
+2,411,575
| New | +$7.54M |
|
12
Caribou Biosciences
CRBU
$164M
| $7.46M | 0.29% |
+4,690,431
| New | +$9.43M |
|
13
Zura Bio
ZURA
$518M
| $7.43M | 0.29% |
+2,970,022
| New | +$10.6M |
|
14
Celcuity
CELC
$4.31B
| $4.57M | 0.18% |
+349,406
| New | +$4.93M |
|
|
EPIX
15
DELISTED
ESSA Pharma
EPIX
| $3M | 0.12% |
+1,675,000
| New | +$5.33M |
|
16
Zentalis Pharmaceuticals
ZNTL
$364M
| $2.89M | 0.11% |
+953,834
| New | +$3.13M |
|
17
Spero Therapeutics
SPRO
$91.5M
| $2.43M | 0.09% |
+2,362,348
| New | +$2.81M |
|
18
NextCure
NXTC
$24.4M
| $1.89M | 0.07% |
+121,546
| New | +$1.79M |
|
19
AN2 Therapeutics
ANTX
$169M
| $987K | 0.04% |
+715,295
| New | +$868K |
|
20
Q32 Bio
QTTB
$255M
| $956K | 0.04% |
+277,777
| New | +$8.77M |
|
21
Bolt Biotherapeutics
BOLT
$8.49M
| $335K | 0.01% |
+31,305
| New | +$378K |
|
22
Ginkgo Bioworks
DNA
$517M
| $28.8K | ﹤0.01% |
+2,928
| New | +$25.1K |
|
23
Senseonics Holdings Inc
SENS
$267M
| $22.7K | ﹤0.01% |
+2,171
| New | +$15.5K |
|
Similar funds
DCC
OCERS
CWMGP
WWA
MFC
RCM
TGIA
GCA
Pfizer's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Pfizer, which disclosed 23 positions worth $2.59B. Its ten largest holdings account for 98% of the portfolio.
Its largest position is Haleon: 197,228,952 shares worth $1.88B.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Pfizer's largest Q4 2024 buy was Haleon: 197,228,952 shares worth $1.88B.
- Pfizer's ten largest holdings make up 98% of its $2.59B portfolio in Q4 2024.
- Pfizer disclosed 23 positions in Q4 2024, its first 13F filing on record.
Based on Pfizer's 13F filing for Q4 2024, filed 14 Feb 2025.